Skip to main content
Equibles
ADPT logo

ADPT · Adaptive Biotechnologies Corp

Track ADPT — free

Use ADPT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ADPT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$24.74 +0.28 (+1.14%) At close · Aug 14
Market Cap
$3.95B
Shares
159.60M

Adaptive Biotechnologies Corp Earnings Call Transcripts

Every quarterly earnings call for Adaptive Biotechnologies Corp (ADPT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲21.2% $47.83M −$45.28M '22 Q3 22-11-03 ▲45.5% $55.20M −$40.13M '22 Q4 23-02-14 ▼2.5% $37.65M −$57.70M '23 Q1 23-05-03 ▲12.1% $48.93M −$47.81M '23 Q2 23-08-02 ▼20.7% $37.92M −$50.30M '23 Q3 23-11-09 ▼17.1% $45.78M −$69.44M '23 Q4 24-02-14 ▲11.2% $41.87M −$47.51M '24 Q1 24-04-05 ▼11.7% $43.19M −$46.22M '24 Q2 24-08-01 ▲22.5% $46.44M −$32.07M '24 Q3 24-11-07 ▲3.7% $47.46M −$33.69M '24 Q4 25-02-11 ▲25.2% $52.44M −$29.85M '25 Q1 25-05-01 ▲36.3% $58.88M −$25.61M '25 Q2 25-08-05 ▲102.4% $93.97M $9.55M '25 Q3 25-11-05 ▲51% $71.68M −$13.58M '25 Q4 26-02-05 ▲35.1% $70.87M −$20.03M '26 Q1 26-05-05 LATEST ▲21.5% $71.55M −$39.79M '26 Q2 26-07-29
Earnings call
FY26 · Q2
2026-07-29
Adaptive Biotechnologies Corp Q2 FY2026 Earnings Call
Confident tone Immune medicine separation Clinical MRD volume growth MRD pricing and reimbursement
Revenue
$71.55M
▲ 21.5% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
William Blair 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Adaptive Biotechnologies Corp Q1 FY2026 Earnings Call
Confident tone MRD revenue and volume growth Biopharma/pharma business and backlog EMR integration and workflows
Revenue
$70.87M
▲ 35.1% YoY
Diluted EPS
$-0.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-05
Adaptive Biotechnologies Corp Q4 FY2025 Earnings Call
Confident tone MRD business growth and profitability ClonoSEQ volume and test growth ASP expansion and payer contracts
Revenue
$71.68M*
▲ 51% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Adaptive Biotechnologies Corp Q3 FY2025 Earnings Call
Confident tone Guideline and reimbursement wins EMR integration and community expansion MRD Pharma and clinical trial demand
Revenue
$93.97M
▲ 102.4% YoY
Diluted EPS
$0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Adaptive Biotechnologies Corp Q2 FY2025 Earnings Call
Confident tone MRD business growth and profitability EMR integration and community expansion MRD pharma backlog and clinical trials
Revenue
$58.88M
▲ 36.3% YoY
Diluted EPS
$-0.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Adaptive Biotechnologies Corp Q1 FY2025 Earnings Call
Confident tone MRD/clonoSEQ clinical volume growth MRD Pharma business Full-year guidance raise
Revenue
$52.44M
▲ 25.2% YoY
Diluted EPS
$-0.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-11
Adaptive Biotechnologies Corp Q4 FY2024 Earnings Call
Confident tone MRD clinical testing growth Pricing and reimbursement (ASP) NeoGenomics commercial partnership
Revenue
$47.46M*
▲ 3.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Adaptive Biotechnologies Corp Q3 FY2024 Earnings Call
Confident tone MRD pharma partnerships and milestones MRD revenue growth and clonoSEQ test volume EMR integration (Epic, Flatiron)
Revenue
$46.44M
▲ 22.5% YoY
Diluted EPS
$-0.88
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Adaptive Biotechnologies Corp Q2 FY2024 Earnings Call
Confident tone MRD clinical growth (clonoSEQ) MRD pharma momentum post-ODAC Immune medicine / autoimmune discovery
Revenue
$43.19M
▼ 11.7% YoY
Diluted EPS
$-1.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-05
Adaptive Biotechnologies Corp Q1 FY2024 Earnings Call
Confident tone MRD Business Growth ODAC and MRD as Endpoint Immune Medicine / Restructuring
Revenue
$41.87M
▲ 11.2% YoY
Diluted EPS
$-1.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-14
Adaptive Biotechnologies Corp Q4 FY2023 Earnings Call
Positive tone MRD / clonoSEQ growth Immune medicine / Genentech partnership ASP and revenue cycle improvement
Revenue
$45.78M*
▼ 17.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Adaptive Biotechnologies Corp Q3 FY2023 Earnings Call
Revenue
$37.92M
▼ 20.7% YoY
Diluted EPS
$-1.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Adaptive Biotechnologies Corp Q2 FY2023 Earnings Call
Revenue
$48.93M
▲ 12.1% YoY
Diluted EPS
$-1.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Adaptive Biotechnologies Corp Q1 FY2023 Earnings Call
Revenue
$37.65M
▼ 2.5% YoY
Diluted EPS
$-1.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-14
Adaptive Biotechnologies Corp Q4 FY2022 Earnings Call
Revenue
$55.20M*
▲ 45.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Adaptive Biotechnologies Corp Q3 FY2022 Earnings Call
Revenue
$47.83M
▲ 21.2% YoY
Diluted EPS
$-1.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Adaptive Biotechnologies Corp Q2 FY2022 Earnings Call
Revenue
$43.66M
▲ 13.4% YoY
Diluted EPS
$-1.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Adaptive Biotechnologies Corp Q1 FY2022 Earnings Call
Revenue
$38.62M
▲ 0.5% YoY
Diluted EPS
$-1.76
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
Adaptive Biotechnologies Corp Q4 FY2021 Earnings Call
Revenue
$37.93M*
▲ 25.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Adaptive Biotechnologies Corp Q3 FY2021 Earnings Call
Revenue
$39.47M
▲ 50.1% YoY
Diluted EPS
$-1.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Adaptive Biotechnologies Corp Q2 FY2021 Earnings Call
Revenue
$38.51M
▲ 83.5% YoY
Diluted EPS
$-1.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Adaptive Biotechnologies Corp Q1 FY2021 Earnings Call
Revenue
$38.44M
▲ 83.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Adaptive Biotechnologies Corp Q4 FY2020 Earnings Call
Revenue
$30.18M*
▲ 24.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Adaptive Biotechnologies Corp Q3 FY2020 Earnings Call
Revenue
$26.30M
▲ 0.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Adaptive Biotechnologies Corp Q2 FY2020 Earnings Call
Revenue
$20.99M
▼ 5.2% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Adaptive Biotechnologies Corp Q1 FY2020 Earnings Call
Revenue
$20.91M
▲ 65.1% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–27 of 27 earnings calls
Key facts CIK 1478320 CUSIP 00650F109 13F (30d) 286 filings 282 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)